MO
Missouri House Bill HB1367

Missouri 2025 Regular Session

Missouri House Bill HB1367 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 FIRSTREGULARSESSION
22 HOUSEBILLNO.1367
33 103RDGENERALASSEMBLY
44 INTRODUCEDBYREPRESENTATIVESELF.
55 2770H.01I JOSEPHENGLER,ChiefClerk
66 ANACT
77 Torepealsection195.017,RSMo,andtoenactinlieuthereoftwonewsectionsrelatingto
88 abortifacientdrugs,withapenaltyprovision.
99 BeitenactedbytheGeneralAssemblyofthestateofMissouri,asfollows:
1010 SectionA.Section195.017,RSMo,isrepealedandtwonewsectionsenactedinlieu
1111 2thereof,tobeknownassections195.017and579.018,toreadasfollows:
1212 195.017.1.Thedepartmentofhealthandseniorservicesshallplaceasubstancein
1313 2ScheduleIifitfindsthatthesubstance:
1414 3 (1)Hashighpotentialforabuse;and
1515 4 (2)HasnoacceptedmedicaluseintreatmentintheUnitedStatesorlacksaccepted
1616 5safetyforuseintreatmentundermedicalsupervision.
1717 6 2.ScheduleI:
1818 7 (1)ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleI;
1919 8 (2)Anyofthefollowingopiates,includingtheirisomers,esters,ethers,salts,and
2020 9saltsofisomers,esters,andethers,unlessspecificallyexcepted,whenevertheexistenceof
2121 10theseisomers,esters,ethersandsaltsispossiblewithinthespecificchemicaldesignation:
2222 11 (a)Acetyl-alpha-methylfentanyl(N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-
2323 12phenylacetamide);
2424 13 (b)Acetylmethadol;
2525 14 (c)Acetylfentanyl(N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
2626 15 (d)Acrylfentanyl(-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide);
2727 16 (e)AH-7921(3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
2828 17 (f)Allylprodine;
2929 EXPLANATION—Matterenclosedinbold-facedbrackets[thus] intheabovebillisnotenactedandis
3030 intendedtobeomittedfromthelaw.Matterinbold-facetypeintheabovebillisproposedlanguage. 18 (g)Alphacetylmethadol(exceptlevoalphacetylmethadol,alsoknownaslevo-alpha-
3131 19acetylmethadollevothadylacetateorLAAM);
3232 20 (h)Alphameprodine;
3333 21 (i)Alphamethadol;
3434 22 (j)Alpha-methylfentanyl(N-1-(alphamethyl-beta-phenyl)ethyl-4-piperidyl)
3535 23propionanilide;1-(1-methyl-2-phenylethyl)-4((N-propanilido)piperidine);
3636 24 (k)Alpha-methylthiofentanyl(N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-
3737 25phenylpropanamide);
3838 26 (l)Benzethidine;
3939 27 (m)Betacetylmethadol;
4040 28 (n)Beta-hydroxyfentanyl(N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-
4141 29phenylpropanamide);
4242 30 (o)Beta-hydroxy-3-methylfentanyl(N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-
4343 31piperidinyl)-N-phenylpropanamide);
4444 32 (p)Betameprodine;
4545 33 (q)Betamethadol;
4646 34 (r)Betaprodine;
4747 35 (s)Clonitazene;
4848 36 (t)Dextromoramide;
4949 37 (u)Diampromide;
5050 38 (v)Cyclopropylfentanyl;
5151 39 (w)Diethylthiambutene;
5252 40 (x)Difenoxin;
5353 41 (y)Dimenoxadol;
5454 42 (z)Dimepheptanol;
5555 43 (aa)Dimethylthiambutene;
5656 44 (bb)Dioxaphetylbutyrate;
5757 45 (cc)Dipipanone;
5858 46 (dd)Ethylmethylthiambutene;
5959 47 (ee)Etonitazene;
6060 48 (ff)Etoxeridine;
6161 49 (gg)4-fluoroisobutyrylfentanyl-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
6262 50isobutyramide;
6363 51 (hh)Furanylfentanyl-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;
6464 52 (ii)Furethidine;
6565 53 (jj)Hydroxypethidine;
6666 54 (kk)Ketobemidone;
6767 HB1367 2 55 (ll)Levomoramide;
6868 56 (mm)Levophenacylmorphan;
6969 57 (nn)3-Methylfentanyl(N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
7070 58phenylproanamide),itsopticalandgeometricisomers,salts,andsaltsofisomers;
7171 59 (oo)3-Methylthiofentanyl(N-((3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-
7272 60phenylpropanamide);
7373 61 (pp)Methoxyacetylfentanyl(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-
7474 62phenylacetamide);
7575 63 (qq)Morpheridine;
7676 64 (rr)MPPP(1-methyl-4-phenyl-4-propionoxypiperidine);
7777 65 (ss)MT-45(1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
7878 66 (tt)Noracymethadol;
7979 67 (uu)Norlevorphanol;
8080 68 (vv)Normethadone;
8181 69 (ww)Norpipanone;
8282 70 (xx)OcfentanilN-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)
8383 71acetamide;
8484 72 (yy)Ortho-fluorofentanyl(N-2-(1-phenethylpiperidin-yl)propionamide);othername
8585 732-fluorofentanyl;
8686 74 (zz)para-fluorobutyrylfentanyl(N-4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
8787 75butyramide;
8888 76 (aaa)Para-fluorofentanyl(N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)
8989 77propanamide;
9090 78 (bbb)PEPAP(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
9191 79 (ccc)Phenadoxone;
9292 80 (ddd)Phenampromide;
9393 81 (eee)Phenomorphan;
9494 82 (fff)Phenoperidine;
9595 83 (ggg)Piritramide;
9696 84 (hhh)Proheptazine;
9797 85 (iii)Properidine;
9898 86 (jjj)Propiram;
9999 87 (kkk)Racemoramide;
100100 88 (lll)Tetrahydrofuranylfentanyl(N-(1-phenethylpiperidin-4-yl)-N-
101101 89phenyltetrahydrofuran-2-carboxamide);
102102 90 (mmm)Thiofentanyl(-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide;
103103 91 (nnn)Tilidine;
104104 HB1367 3 92 (ooo)Trimeperidine;
105105 93 (3)Anyofthefollowingopiumderivatives,theirsalts,isomersandsaltsofisomers
106106 94unlessspecificallyexcepted,whenevertheexistenceofthesesalts,isomersandsaltsof
107107 95isomersispossiblewithinthespecificchemicaldesignation:
108108 96 (a)Acetorphine;
109109 97 (b)Acetyldihydrocodeine;
110110 98 (c)Benzylmorphine;
111111 99 (d)Codeinemethylbromide;
112112 100 (e)Codeine-N-Oxide;
113113 101 (f)Cyprenorphine;
114114 102 (g)Desomorphine;
115115 103 (h)Dihydromorphine;
116116 104 (i)Drotebanol;
117117 105 (j)Etorphine(excepthydrochloridesalt);
118118 106 (k)Heroin;
119119 107 (l)Hydromorphinol;
120120 108 (m)Methyldesorphine;
121121 109 (n)Methyldihydromorphine;
122122 110 (o)Morphinemethylbromide;
123123 111 (p)Morphinemethylsulfonate;
124124 112 (q)Morphine-N-Oxide;
125125 113 (r)Myrophine;
126126 114 (s)Nicocodeine;
127127 115 (t)Nicomorphine;
128128 116 (u)Normorphine;
129129 117 (v)Pholcodine;
130130 118 (w)Thebacon;
131131 119 (4)AnyofthefollowingopiatesimilarsyntheticsubstancesscheduledbytheU.S.
132132 120DrugEnforcementAdministrationassubstancesthatshareapharmacologicalprofilesimilar
133133 121tofentanyl,morphine,andothersyntheticopioids,unlessspecificallyexceptedorunless
134134 122listedinanotherschedule:
135135 123 (a)Butyrylfentanyl(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
136136 124 (b)U-47700(3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]–methylbenzamide).
137137 125 (5)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityof
138138 126thefollowinghallucinogenicsubstances,theirsalts,isomersandsaltsofisomers,unless
139139 127specificallyexcepted,whenevertheexistenceofthesesalts,isomers,andsaltsofisomersis
140140 128possiblewithinthespecificchemicaldesignation:
141141 HB1367 4 129 (a)Alpha-ethyltryptamine;
142142 130 (b)4-bromo-2,5-dimethoxyamphetamine;
143143 131 (c)4-bromo-2,5-dimethoxyphenethylamine;
144144 132 (d)2,5-dimethoxyamphetamine;
145145 133 (e)2,5-dimethoxy-4-ethylamphetamine;
146146 134 (f)2,5-dimethoxy-4-(n)-propylthiophenethylamine;
147147 135 (g)2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;
148148 136 (h)2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;
149149 137 (i)2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;
150150 138 (j)2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;
151151 139 (k)2-(2,5-Dimethoxyphenyl)ethanamine;
152152 140 (l)2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine;
153153 141 (m)2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine;
154154 142 (n)2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine;
155155 143 (o)2-(4-Isopropylthio)-2,5-dimethoxyphenyl)ethanamine;
156156 144 (p)4-methoxyamphetamine;
157157 145 (q)5-methoxy-3,4-methylenedioxyamphetamine;
158158 146 (r)4-methyl-2,5-dimethoxyamphetamine;
159159 147 (s)3,4-methylenedioxyamphetamine;
160160 148 (t)3,4-methylenedioxymethamphetamine;
161161 149 (u)3,4-methylenedioxy-N-ethylamphetamine;
162162 150 (v)N-hydroxy-3,4-methylenedioxyamphetamine;
163163 151 (w)3,4,5-trimethoxyamphetamine;
164164 152 (x)5-MeO-DMTor5-methoxy-N,N-dimethyltryptamine;
165165 153 (y)Alpha-methyltryptamine;
166166 154 (z)Bufotenine;
167167 155 (aa)Diethyltryptamine;
168168 156 (bb)Dimethyltryptamine;
169169 157 (cc)5-methoxy-N,N-diisopropyltryptamine;
170170 158 (dd)Ibogaine;
171171 159 (ee)Lysergicaciddiethylamide;
172172 160 (ff)Marijuanaormarihuana,exceptindustrialhemp;
173173 161 (gg)Mescaline;
174174 162 (hh)Parahexyl;
175175 163 (ii)Peyote,toincludeallpartsoftheplantpresentlyclassifiedbotanicallyas
176176 164LophophorawilliamsiiLemaire,whethergrowingornot;theseedsthereof;anyextractfrom
177177 HB1367 5 165anypartofsuchplant;andeverycompound,manufacture,salt,derivative,mixtureor
178178 166preparationoftheplant,itsseedorextracts;
179179 167 (jj)N-ethyl-3-piperidylbenzilate;
180180 168 (kk)N-methyl-3-piperidylbenzilate;
181181 169 (ll)Psilocybin;
182182 170 (mm)Psilocyn;
183183 171 (nn)TetrahydrocannabinolsnaturallycontainedinaplantofthegenusCannabis
184184 172(cannabisplant),exceptindustrialhemp,aswellassyntheticequivalentsofthesubstances
185185 173containedinthecannabisplant,orintheresinousextractivesofsuchplant,orsynthetic
186186 174substances,derivativesandtheirisomers,orboth,withsimilarchemicalstructureand
187187 175pharmacologicalactivitytothosesubstancescontainedintheplant,suchasthefollowing:
188188 176 a.1cisortranstetrahydrocannabinolandtheiropticalisomers;
189189 177 b.6cisortranstetrahydrocannabinolandtheiropticalisomers;
190190 178 c.3,4cisortranstetrahydrocannabinolandtheiropticalisomers;
191191 179 d.Anycompoundsofthesestructures,regardlessofnumericaldesignationofatomic
192192 180positionscovered;
193193 181 (oo)Ethylamineanalogofphencyclidine;
194194 182 (pp)Pyrrolidineanalogofphencyclidine;
195195 183 (qq)Thiopheneanalogofphencyclidine;
196196 184 (rr)1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
197197 185 (ss)Salviadivinorum;
198198 186 (tt)SalvinorinA;
199199 187 (uu)Syntheticcannabinoids:
200200 188 a.Anycompoundstructurallyderivedfrom3-(1-naphthoyl)indoleor1H-indol-3-yl-
201201 189(1-naphthyl)methanebysubstitutionatthenitrogenatomoftheindoleringbyalkyl,
202202 190haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-
203203 191(4-morpholinyl)ethylgroup,whetherornotfurthersubstitutedintheindoleringtoanyextent,
204204 192whetherornotsubstitutedinthenaphthylringtoanyextent.Including,butnotlimitedto:
205205 193 (i)AM2201,or1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
206206 194 (ii)JWH-007,or1-pentyl-2-methyl-3-(1-naphthoyl)indole;
207207 195 (iii)JWH-015,or1-propyl-2-methyl-3-(1-naphthoyl)indole;
208208 196 (iv)JWH-018,or1-pentyl-3-(1-naphthoyl)indole;
209209 197 (v)JWH-019,or1-hexyl-3-(1-naphthoyl)indole;
210210 198 (vi)JWH-073,or1-butyl-3-(1-naphthoyl)indole;
211211 199 (vii)JWH-081,or1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
212212 200 (viii)JWH-098,or1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
213213 201 (ix)JWH-122,or1-pentyl-3-(4-methyl-1-naphthoyl)indole;
214214 HB1367 6 202 (x)JWH-164,or1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
215215 203 (xi)JWH-200,or1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
216216 204 (xii)JWH-210,or1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
217217 205 (xiii)JWH-398,or1-pentyl-3-(4-chloro-1-naphthoyl)indole;
218218 206 b.Anycompoundstructurallyderivedfrom3-(1-naphthoyl)pyrrolebysubstitutionat
219219 207thenitrogenatomofthepyrroleringbyalkyl,haloalkyl,alkenyl,cycloalkylmethyl,
220220 208cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)ethylgroup,whether
221221 209ornotfurthersubstitutedinthepyrroleringtoanyextent,whetherornotsubstitutedinthe
222222 210naphthylringtoanyextent;
223223 211 c.Anycompoundstructurallyderivedfrom1-(1-naphthylmethyl)indeneby
224224 212substitutionatthe3-positionoftheindeneringbyalkyl,haloalkyl,alkenyl,
225225 213cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)
226226 214ethylgroup,whetherornotfurthersubstitutedintheindeneringtoanyextent,whetherornot
227227 215substitutedinthenaphthylringtoanyextent;
228228 216 d.Anycompoundstructurallyderivedfrom3-phenylacetylindolebysubstitutionat
229229 217thenitrogenatomoftheindoleringwithalkyl,haloalkyl,alkenyl,cycloalkylmethyl,
230230 218cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)ethylgroup,whether
231231 219ornotfurthersubstitutedintheindoleringtoanyextent,whetherornotsubstitutedinthe
232232 220phenylringtoanyextent.Including,butnotlimitedto:
233233 221 (i)JWH-201,or1-pentyl-3-(4-methoxyphenylacetyl)indole;
234234 222 (ii)JWH-203,or1-pentyl-3-(2-chlorophenylacetyl)indole;
235235 223 (iii)JWH-250,or1-pentyl-3-(2-methoxyphenylacetyl)indole;
236236 224 (iv)JWH-251,or1-pentyl-3-(2-methylphenylacetyl)indole;
237237 225 (v)RCS-8,or1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
238238 226 e.Anycompoundstructurallyderivedfrom2-(3-hydroxycyclohexyl)phenolby
239239 227substitutionatthe5-positionofthephenolicringbyalkyl,haloalkyl,alkenyl,
240240 228cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)
241241 229ethylgroup,whetherornotsubstitutedinthecyclohexylringtoanyextent.Including,but
242242 230notlimitedtoCP47,497andhomologues,or2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-
243243 231methyloctan-2-yl)phenol,wheresidechainn=5,andhomologueswheresidechainn-4,6,or
244244 2327;
245245 233 f.Anycompoundcontaininga3-(benzoyl)indolestructurewithsubstitutionatthe
246246 234nitrogenatomoftheindoleringbyalkyl,haloalkyl,alkenyl,cycloalkylmethyl,
247247 235cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)ethylgroup,
248248 236whetherornotfurthersubstitutedintheindoleringtoanyextentandwhetherornot
249249 237substitutedinthephenylringtoanyextent.Including,butnotlimitedto:
250250 238 (i)AM-694,or1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
251251 HB1367 7 239 (ii)RCS-4,or1-pentyl-3-(4-methoxybenzoyl)indole(SR-19andRCS-4);
252252 240 g.CP50,556-1,or[(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-
253253 2412-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;
254254 242 h.HU-210,or(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
255255 2436a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
256256 244 i.HU-211,orDexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
257257 245methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
258258 246 j.Dimethylheptylpyran,orDMHP;
259259 247 (6)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
260260 248followingsubstanceshavingadepressanteffectonthecentralnervoussystem,includingtheir
261261 249salts,isomersandsaltsofisomerswhenevertheexistenceofthesesalts,isomersandsaltsof
262262 250isomersispossiblewithinthespecificchemicaldesignation:
263263 251 (a)Gamma-hydroxybutyricacid;
264264 252 (b)Mecloqualone;
265265 253 (c)Methaqualone;
266266 254 (7)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
267267 255followingsubstanceshavingastimulanteffectonthecentralnervoussystem,includingtheir
268268 256salts,isomersandsaltsofisomers:
269269 257 (a)Aminorex;
270270 258 (b)N-benzylpiperazine;
271271 259 (c)Cathinone;
272272 260 (d)Fenethylline;
273273 261 (e)3-Fluoromethcathinone;
274274 262 (f)4-Fluoromethcathinone;
275275 263 (g)Mephedrone,or4-methylmethcathinone;
276276 264 (h)Methcathinone;
277277 265 (i)4-methoxymethcathinone;
278278 266 (j)(+,-)cis-4-methylaminorex((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-
279279 267oxazolamine);
280280 268 (k)Methylenedioxypyrovalerone,MDPV,or1-(1,3-Benzodioxol-5-yl)-2-(1-
281281 269pyrrolidinyl)-1-pentanone;
282282 270 (l)Methylone,or3,4-Methylenedioxymethcathinone;
283283 271 (m)4-Methyl-alpha-pyrrolidinobutiophenone,orMPBP;
284284 272 (n)N-ethylamphetamine;
285285 273 (o)N,N-dimethylamphetamine;
286286 274 (p)Quinolin-8-yl1-pentyl-1H-indole-3-carboxylate(PB-22;QUPIC);
287287 HB1367 8 275 (q)Quinolin-8-yl1-(5-fluoropentyl)-1H-indole-3-carboxylate(5-fluoro-PB-22;5F-
288288 276PB-22);
289289 277 (r)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
290290 278carboxamide(AB-FUBINACA);
291291 279 (s)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide
292292 280(ADB-PINACA);
293293 281 (8)Atemporarylistingofsubstancessubjecttoemergencyschedulingunderfederal
294294 282lawshallincludeanymaterial,compound,mixtureorpreparationwhichcontainsany
295295 283quantityofthefollowingsubstances:
296296 284 (a)(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone,itsoptical,
297297 285positional,andgeometricisomers,salts,andsaltsofisomers;
298298 286 (b)[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone,
299299 287itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
300300 288 (c)N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,itsoptical,positional,and
301301 289geometricisomers,salts,andsaltsofisomers;
302302 290 (d)2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,itsoptical,
303303 291positional,andgeometricisomers,salts,andsaltsofisomers;
304304 292 (e)2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,itsoptical,
305305 293positional,andgeometricisomers,salts,andsaltsofisomers;
306306 294 (f)2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,itsoptical,
307307 295positional,andgeometricisomers,salts,andsaltsofisomers;
308308 296 (g)4-methyl-N-ethylcathinone,itsoptical,positional,andgeometricisomers,salts,
309309 297andsaltsofisomers;
310310 298 (h)4-methyl-alpha-pyrrolidinopropiophenone,itsoptical,positional,andgeometric
311311 299isomers,salts,andsaltsofisomers;
312312 300 (i)Alpha-pyrrolidinopentiophenone,itsoptical,positional,andgeometricisomers,
313313 301salts,andsaltsofisomers;
314314 302 (j)Butylone,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
315315 303 (k)Pentedrone,itsoptical,positional,andgeometricisomers,salts,andsaltsof
316316 304isomers;
317317 305 (l)Pentylone,itsoptical,positional,andgeometricisomers,salts,andsaltsof
318318 306isomers;
319319 307 (m)Naphyrone,itsoptical,positional,andgeometricisomers,salts,andsaltsof
320320 308isomers;
321321 309 (n)Alpha-pyrrolidinobutiophenone,itsoptical,positional,andgeometricisomers,
322322 310salts,andsaltsofisomers;
323323 HB1367 9 311 (o)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
324324 312carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
325325 313 (p)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide,its
326326 314optical,positional,andgeometricisomers,salts,andsaltsofisomers;
327327 315 (q)[1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1-yl)methanone,itsoptical,
328328 316positional,andgeometricisomers,salts,andsaltsofisomers;
329329 317 (r)N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide,
330330 318itsisomers,esters,ethers,salts,andsaltsofisomers,esters,andethers;
331331 319 (s)N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,itsoptical,positional,and
332332 320geometricisomers,salts,andsaltsofisomers;
333333 321 (t)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
334334 322carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
335335 323 (u)methyl2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-
336336 324dimethylbutanoate,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
337337 325 (v)methyl2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,its
338338 326optical,positional,andgeometricisomers,salts,andsaltsofisomers;
339339 327 (w)N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide,itsoptical,
340340 328positional,andgeometricisomers,salts,andsaltsofisomers;
341341 329 (x)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
342342 330carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
343343 331 (y)methyl2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-
344344 332dimethylbutanoate,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
345345 333 (z)methyl2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-
346346 334dimethylbutanoate,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
347347 335 (aa)N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide,itsisomers,
348348 336esters,ethers,salts,andsaltsofisomers,esters,andethers;
349349 337 (bb)methyl2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,
350350 338itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
351351 339 (cc)N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide,itsisomers,
352352 340esters,ethers,salts,andsaltsofisomers,esters,andethers;
353353 341 (dd)N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide,itsisomers,esters,ethers,
354354 342salts,andsaltsofisomers,esters,andethers;
355355 343 (ee)N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide,itsisomers,esters,
356356 344ethers,salts,andsaltsofisomers,esters,andethers;
357357 345 (ff)N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide,itsisomers,
358358 346esters,ethers,salts,andsaltsofisomers,esters,andethers;
359359 HB1367 10 347 (gg)N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide,itsisomers,
360360 348esters,ethers,salts,andsaltsofisomers,esters,andethers;
361361 349 (hh)N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide,itsisomers,esters,
362362 350ethers,salts,andsaltsofisomers,esters,andethers;
363363 351 (ii)N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide,itsisomers,
364364 352esters,ethers,salts,andsaltsofisomers,esters,andethers;
365365 353 (jj)Fentanyl-relatedsubstances,theirisomers,esters,ethers,salts,andsaltsof
366366 354isomers,esters,andethers.Fentanyl-relatedsubstanceshallmeananysubstancenot
367367 355otherwiselistedunderanotherDrugEnforcementAdministrationControlledSubstanceCode
368368 356Number,andforwhichnoexemptionorapprovalisineffectundersection505oftheFederal
369369 357Food,Drug,andCosmeticAct,21U.S.C.Section355,thatisstructurallyrelatedtofentanyl
370370 358byoneormoreofthefollowingmodifications:
371371 359 a.Replacementofthephenylportionofthephenethylgroupbyanymonocycle,
372372 360whetherornotfurthersubstitutedinoronthemonocycle;
373373 361 b.Substitutioninoronthephenethylgroupwithalkyl,alkenyl,alkoxyl,hydroxyl,
374374 362halo,haloalkyl,aminoornitrogroups;
375375 363 c.Substitutioninoronthepiperidineringwithalkyl,alkenyl,alkoxyl,ester,ether,
376376 364hydroxyl,aminoornitrogroups;
377377 365 d.Replacementoftheanilineringwithanyaromaticmonocycle,whetherornot
378378 366furthersubstitutedinoronthearomaticmonocycle;or
379379 367 e.ReplacementoftheN-propionylgroupbyanotheracylgroup;
380380 368 (kk)Naphthalen-1-yl1-(5-fluoropentyl)-1H-indole-3-carboxylate,itsoptical,
381381 369positional,andgeometricisomers,salts,andsaltsofisomers(NM2201;CBL2201);
382382 370 (ll)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
383383 371carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(5F-
384384 372AB-PINACA);
385385 373 (mm)1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide,its
386386 374optical,positional,andgeometricisomers,salts,andsaltsofisomers(4-CN-CUMYL-
387387 375BUTINACA;4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-4CN-
388388 376BINACA;SGT-78);
389389 377 (nn)methyl2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate,
390390 378itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(MMB-CHMICA,
391391 379AMB-CHMICA);
392392 380 (oo)1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-
393393 381carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(5F-
394394 382CUMYL-P7AICA);
395395 HB1367 11 383 (pp)N-ethylpentylone,itsoptical,positional,andgeometricisomers,salts,andsalts
396396 384ofisomers(ephylone,1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one;
397397 385 (qq)ethyl2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate,
398398 386itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialname:5F-
399399 387EDMB-PINACA);
400400 388 (rr)methyl2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate,
401401 389itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialname:5F-
402402 390MDMB-PICA);
403403 391 (ss)N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide,itsoptical,
404404 392positional,andgeometricisomers,salts,andsaltsofisomers(trivialnames:FUB-AKB48;
405405 393FUB-APINACA;AKB48N-(4-FLUOROBENZYL));
406406 394 (tt)1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide,its
407407 395optical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialnames:5F-
408408 396CUMYL-PINACA;SGT-25);
409409 397 (uu)(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone,
410410 398itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialname:FUB-
411411 399144);
412412 400 (vv)N-ethylhexedrone,itsoptical,positional,andgeometricisomers,salts,andsalts
413413 401ofisomers(Othername:2-(ethylamino)-1-phenylhexan-1-one);
414414 402 (ww)alpha-pyrrolidinohexanophenone,itsoptical,positional,andgeometricisomers,
415415 403salts,andsaltsofisomers(Othernames:α-PHP;alpha-pyrrolidinohexiophenone;1-phenyl-2-
416416 404(pyrrolidin-1-yl)hexan-1-one);
417417 405 (xx)4-methyl-alpha-ethylaminopentiophenone,itsoptical,positional,andgeometric
418418 406isomers,salts,andsaltsofisomers;(Othernames:4-MEAP;2-(ethylamino)-1-(4-
419419 407methylphenyl)pentan-1-one);
420420 408 (yy)4'-methyl-alpha-pyrrolidinohexiophenone,itsoptical,positional,andgeometric
421421 409isomers,salts,andsaltsofisomers(Othernames:MPHP;4'-methyl-alpha-
422422 410pyrrolidinohexanophenone;1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
423423 411 (zz)alpha-pyrrolidinoheptaphenone,itsoptical,positional,andgeometricisomers,
424424 412salts,andsaltsofisomers(Othernames:PV8;1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
425425 413 (aaa)4'-chloro-alpha-pyrrolidinovalerophenone,itsoptical,positional,andgeometric
426426 414isomers,salts,andsaltsofisomers(Othernames:4-chloro-α-PVP; 4'-chloro-alpha-
427427 415pyrrolidinopentiophenone;1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
428428 416 (9)Khat,toincludeallpartsoftheplantpresentlyclassifiedbotanicallyascatha
429429 417edulis,whethergrowingornot;theseedsthereof;anyextractfromanypartofsuchplant;and
430430 418everycompound,manufacture,salt,derivative,mixture,orpreparationoftheplant,itsseedor
431431 419extracts.
432432 HB1367 12 420 3.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinScheduleII
433433 421ifitfindsthat:
434434 422 (1)Thesubstancehashighpotentialforabuse;
435435 423 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
436436 424States,orcurrentlyacceptedmedicalusewithsevererestrictions;and
437437 425 (3)Theabuseofthesubstancemayleadtoseverepsychicorphysicaldependence.
438438 426 4.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleII:
439439 427 (1)Anyofthefollowingsubstanceswhetherproduceddirectlyorindirectlyby
440440 428extractionfromsubstancesofvegetableorigin,orindependentlybymeansofchemical
441441 429synthesis,orbycombinationofextractionandchemicalsynthesis:
442442 430 (a)Opiumandopiate;andanysalt,compound,derivativeorpreparationofopiumor
443443 431opiate,excludingapomorphine,thebaine-derivedbutorphanol,dextrorphan,nalbuphine,
444444 432nalmefene,naloxegol,naloxone,andnaltrexone,andtheirrespectivesalts,butincludingthe
445445 433following:
446446 434 a.Rawopium;
447447 435 b.Opiumextracts;
448448 436 c.Opiumfluid;
449449 437 d.Powderedopium;
450450 438 e.Granulatedopium;
451451 439 f.Tinctureofopium;
452452 440 g.Codeine;
453453 441 h.Dihydroetorphine;
454454 442 i.Ethylmorphine;
455455 443 j.Etorphinehydrochloride;
456456 444 k.Hydrocodone;
457457 445 l.Hydromorphone;
458458 446 m.Metopon;
459459 447 n.Morphine;
460460 448 o.Oripavine;
461461 449 p.Oxycodone;
462462 450 q.Oxymorphone;
463463 451 r.Thebaine;
464464 452 (b)Anysalt,compound,derivative,orpreparationthereofwhichischemically
465465 453equivalentoridenticalwithanyofthesubstancesreferredtointhissubdivision,butnot
466466 454includingtheisoquinolinealkaloidsofopium;
467467 455 (c)Opiumpoppyandpoppystraw;
468468 HB1367 13 456 (d)Cocaleavesandanysalt,compound,derivative,orpreparationofcocaleaves,and
469469 457anysalt,compound,derivative,orpreparationthereofwhichischemicallyequivalentor
470470 458identicalwithanyofthesesubstances,butnotincludingthefollowing:
471471 459 a.Decocainizedcocaleavesorextractionsofcocaleaves,whichextractionsdonot
472472 460containcocaineorecgonine;or
473473 461 b.Ioflupane;
474474 462 (e)Concentrateofpoppystraw(thecrudeextractofpoppystrawineitherliquid,
475475 463solidorpowderformwhichcontainsthephenanthrenealkaloidsoftheopiumpoppy);
476476 464 (2)Anyofthefollowingopiates,includingtheirisomers,esters,ethers,salts,and
477477 465saltsofisomers,whenevertheexistenceoftheseisomers,esters,ethers,andsaltsispossible
478478 466withinthespecificchemicaldesignation,dextrorphanandlevopropoxypheneexcepted:
479479 467 (a)Alfentanil;
480480 468 (b)Alphaprodine;
481481 469 (c)Anileridine;
482482 470 (d)Bezitramide;
483483 471 (e)Bulkdextropropoxyphene;
484484 472 (f)Carfentanil;
485485 473 (g)Dihydrocodeine;
486486 474 (h)Diphenoxylate;
487487 475 (i)Fentanyl;
488488 476 (j)Isomethadone;
489489 477 (k)Levo-alphacetylmethadol;
490490 478 (l)Levomethorphan;
491491 479 (m)Levorphanol;
492492 480 (n)Metazocine;
493493 481 (o)Methadone;
494494 482 (p)Methadone-Intermediate,4-cyano-2-dimethylamino-4,4-diphenylbutane;
495495 483 (q)Moramide-Intermediate,2-methyl-3-morpholino-1,1-diphenylpropane-
496496 484carboxylicacid;
497497 485 (r)Pethidine(meperidine);
498498 486 (s)Pethidine-Intermediate-A,4-cyano-1-methyl-4-phenylpiperidine;
499499 487 (t)Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4-carboxylate;
500500 488 (u)Pethidine-Intermediate-C,1-methyl-4-phenylpiperdine-4-carboxylicacid;
501501 489 (v)Phenazocine;
502502 490 (w)Piminodine;
503503 491 (x)Racemethorphan;
504504 492 (y)Racemorphan;
505505 HB1367 14 493 (z)Remifentanil;
506506 494 (aa)Sufentanil;
507507 495 (bb)Tapentadol;
508508 496 (cc)Thiafentanil;
509509 497 (3)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
510510 498thefollowingsubstanceshavingastimulanteffectonthecentralnervoussystem:
511511 499 (a)Amphetamine,itssalts,opticalisomers,andsaltsofitsopticalisomers;
512512 500 (b)Lisdexamfetamine,itssalts,isomers,andsaltsofitsisomers;
513513 501 (c)Methamphetamine,itssalts,isomers,andsaltsofitsisomers;
514514 502 (d)Phenmetrazineanditssalts;
515515 503 (e)Methylphenidate;
516516 504 (4)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
517517 505thefollowingsubstanceshavingadepressanteffectonthecentralnervoussystem,including
518518 506itssalts,isomers,andsaltsofisomerswhenevertheexistenceofthosesalts,isomers,andsalts
519519 507ofisomersispossiblewithinthespecificchemicaldesignation:
520520 508 (a)Amobarbital;
521521 509 (b)Glutethimide;
522522 510 (c)Pentobarbital;
523523 511 (d)Phencyclidine;
524524 512 (e)Secobarbital;
525525 513 (5)Hallucinogenicsubstances:
526526 514 (a)Anymaterialorcompoundwhichcontainsanyquantityofnabilone;
527527 515 (b)Dronabinol[(-)-Δ-9-transtetrahydrocannabinol]inanoralsolutioninadrug
528528 516productapprovedformarketingbytheU.S.FoodandDrugAdministration;
529529 517 (6)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
530530 518thefollowingsubstances:
531531 519 (a)Immediateprecursortoamphetamineandmethamphetamine:Phenylacetone;
532532 520 (b)Immediateprecursorstophencyclidine(PCP):
533533 521 a.1-phenylcyclohexylamine;
534534 522 b.1-piperidinocyclohexanecarbonitrile(PCC);
535535 523 (c)Immediateprecursortofentanyl:4-anilino-N-phenethyl-4-piperidine(ANPP);
536536 524 (7)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
537537 525thefollowingalkylnitrites:
538538 526 (a)Amylnitrite;
539539 527 (b)Butylnitrite.
540540 528 5.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinScheduleIII
541541 529ifitfindsthat:
542542 HB1367 15 530 (1)Thesubstancehasapotentialforabuselessthanthesubstanceslistedin
543543 531SchedulesIandII;
544544 532 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
545545 533States;and
546546 534 (3)Abuseofthesubstancemayleadtomoderateorlowphysicaldependenceorhigh
547547 535psychologicaldependence.
548548 536 6.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleIII:
549549 537 (1)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
550550 538thefollowingsubstanceshavingapotentialforabuseassociatedwithastimulanteffectonthe
551551 539centralnervoussystem:
552552 540 (a)Benzphetamine;
553553 541 (b)Chlorphentermine;
554554 542 (c)Clortermine;
555555 543 (d)Phendimetrazine;
556556 544 (2)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityor
557557 545saltofthefollowingsubstancesorsaltshavingadepressanteffectonthecentralnervous
558558 546system:
559559 547 (a)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityor
560560 548saltofthefollowingsubstancescombinedwithoneormoreactivemedicinalingredients:
561561 549 a.Amobarbital;
562562 550 b.Secobarbital;
563563 551 c.Pentobarbital;
564564 552 (b)Anysuppositorydosageformcontaininganyquantityorsaltofthefollowing:
565565 553 a.Amobarbital;
566566 554 b.Secobarbital;
567567 555 c.Pentobarbital;
568568 556 (c)Anysubstancewhichcontainsanyquantityofaderivativeofbarbituricacidorits
569569 557salt;
570570 558 (d)Chlorhexadol;
571571 559 (e)Embutramide;
572572 560 (f)Gammahydroxybutyricacidanditssalts,isomers,andsaltsofisomerscontained
573573 561inadrugproductforwhichanapplicationhasbeenapprovedunderSection505ofthefederal
574574 562Food,Drug,andCosmeticAct;
575575 563 (g)Ketamine,itssalts,isomers,andsaltsofisomers;
576576 564 (h)Lysergicacid;
577577 565 (i)Lysergicacidamide;
578578 566 (j)Methyprylon;
579579 HB1367 16 567 (k)Perampanel,anditssalts,isomers,andsaltsofisomers;
580580 568 (l)Sulfondiethylmethane;
581581 569 (m)Sulfonethylmethane;
582582 570 (n)Sulfonmethane;
583583 571 (o)Tiletamineandzolazepamoranysaltthereof;
584584 572 (3)Nalorphine;
585585 573 (4)Anymaterial,compound,mixture,orpreparationcontaininglimitedquantitiesof
586586 574anyofthefollowingnarcoticdrugsortheirsalts:
587587 575 (a)Notmorethan1.8gramsofcodeineperonehundredmillilitersornotmorethan
588588 576ninetymilligramsperdosageunit,withanequalorgreaterquantityofanisoquinoline
589589 577alkaloidofopium;
590590 578 (b)Notmorethan1.8gramsofcodeineperonehundredmillilitersornotmorethan
591591 579ninetymilligramsperdosageunitwithoneormoreactive,nonnarcoticingredientsin
592592 580recognizedtherapeuticamounts;
593593 581 (c)Notmorethan1.8gramsofdihydrocodeineperonehundredmillilitersornot
594594 582morethanninetymilligramsperdosageunit,withoneormoreactive,nonnarcoticingredients
595595 583inrecognizedtherapeuticamounts;
596596 584 (d)Notmorethanthreehundredmilligramsofethylmorphineperonehundred
597597 585millilitersornotmorethanfifteenmilligramsperdosageunit,withoneormoreactive,
598598 586nonnarcoticingredientsinrecognizedtherapeuticamounts;
599599 587 (e)Notmorethanfivehundredmilligramsofopiumperonehundredmillilitersorper
600600 588onehundredgramsornotmorethantwenty-fivemilligramsperdosageunit,withoneormore
601601 589activenonnarcoticingredientsinrecognizedtherapeuticamounts;
602602 590 (f)Notmorethanfiftymilligramsofmorphineperonehundredmillilitersorperone
603603 591hundredgrams,withoneormoreactive,nonnarcoticingredientsinrecognizedtherapeutic
604604 592amounts;
605605 593 (5)Anymaterial,compound,mixture,orpreparationcontaininganyofthefollowing
606606 594narcoticdrugsortheirsalts:Buprenorphine;
607607 595 (6)Anabolicsteroids.Anydrugorhormonalsubstance,chemicallyand
608608 596pharmacologicallyrelatedtotestosterone(otherthanestrogens,progestins,corticosteroids,
609609 597anddehydroepiandrosterone)thatpromotesmusclegrowth,exceptananabolicsteroidwhich
610610 598isexpresslyintendedforadministrationthroughimplantstocattleorothernonhumanspecies
611611 599andwhichhasbeenapprovedbytheSecretaryofHealthandHumanServicesforthat
612612 600administration.Ifanypersonprescribes,dispenses,ordistributessuchsteroidforhumanuse,
613613 601suchpersonshallbeconsideredtohaveprescribed,dispensed,ordistributedananabolic
614614 602steroidwithinthemeaningofthissubdivision.Unlessspecificallyexceptedorunlesslisted
615615 HB1367 17 603inanotherschedule,anymaterial,compound,mixtureorpreparationcontaininganyquantity
616616 604ofthefollowingsubstances,includingitssalts,estersandethers:
617617 605 (a)3ß,17ß-dihydroxy-5α-androstane;
618618 606 (b)3α,17β-dihydroxy-5α-androstane;
619619 607 (c)5α-androstan-3,17-dione;
620620 608 (d)1-androstenediol(3β,17β-dihydroxy-5α-androst-1-ene);
621621 609 (e)1-androstenediol(3α,17β-dihydroxy-5α-androst-1-ene);
622622 610 (f)4-androstenediol(3β,17β-dihydroxy-androst-4-ene);
623623 611 (g)5-androstenediol(3β,17β-dihydroxy-androst-5-ene);
624624 612 (h)1-androstenedione([5α]-androst-1-en-3,17-dione);
625625 613 (i)4-androstenedione(androst-4-en-3,17-dione);
626626 614 (j)5-androstenedione(androst-5-en-3,17-dione);
627627 615 (k)Bolasterone(7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
628628 616 (l)Boldenone(17β-hydroxyandrost-1,4,-diene-3-one);
629629 617 (m)Boldione;
630630 618 (n)Calusterone(7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
631631 619 (o)Clostebol(4-chloro-17β-hydroxyandrost-4-en-3-one);
632632 620 (p)Dehydrochloromethyltestosterone(4-chloro-17β-hydroxy-17α-methyl-androst-
633633 6211,4-dien-3-one);
634634 622 (q)Desoxymethyltestosterone;
635635 623 (r)4-dihydrotestosterone(17ß-hydroxy-androstan-3-one);
636636 624 (s)Drostanolone(17ß-hydroxy-2α-methyl-5α-androstan-3-one);
637637 625 (t)Ethylestrenol(17α-ethyl-17ß-hydroxyestr-4-ene);
638638 626 (u)Fluoxymesterone(9-fluoro-17α-methyl-1 1ß,17ß-dihydroxyandrost-4-en-3-one);
639639 627 (v)Formebolone(2-formyl-17α-methyl-1 1α,17ß-dihydroxyandrost-1,4-dien-3-one);
640640 628 (w)Furazabol(17α-methyl-17ß-hydroxyandrostano[2,3-c]-furazan);
641641 629 (x)13ß-ethyl-17ß-hydroxygon-4-en-3-one;
642642 630 (y)4-hydroxytestosterone(4,17ß-dihydroxy-androst-4-en-3-one);
643643 631 (z)4-hydroxy-19-nortestosterone(4,17ß-dihydroxy-estr-4-en-3-one);
644644 632 (aa)Mestanolone(17α-methyl-17ß-hydroxy-5α-androstan-3-one);
645645 633 (bb)Mesterolone(1α-methyl-17ß-hydroxy-[5α]-androstan-3-one);
646646 634 (cc)Methandienone(17α-methyl-17ß-hydroxyandrost-1,4-dien-3-one);
647647 635 (dd)Methandriol(17α-methyl-3ß,17ß-dihydroxyandrost-5-ene);
648648 636 (ee)Methasterone(2α,17α-dimethyl-5α-androstan-17β-ol-3-one);
649649 637 (ff)Methenolone(1-methyl-17ß-hydroxy-5α-androst-1-en-3-one);
650650 638 (gg)17α-methyl-3β,17β-dihydroxy-5α-androstane;
651651 639 (hh)17α-methyl-3α,17β-dihydroxy-5α-androstane;
652652 HB1367 18 640 (ii)17α-methyl-3β,17β-dihydroxyandrost-4-ene;
653653 641 (jj)17α-methyl-4-hydroxynandrolone(17α-methyl-4-hydroxy-17β-hydroxyestr -4-en-
654654 6423-one);
655655 643 (kk)Methyldienolone(17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);
656656 644 (ll)Methyltrienolone(17α-methyl-17β-hydroxyestra-4,9,1 1-trien-3-one);
657657 645 (mm)Methyltestosterone(17α-methyl-17β-hydroxyandrost-4-en-3-one);
658658 646 (nn)Mibolerone(7α,17α-dimethyl-17β-hydroxyestr-4- en-3-one);
659659 647 (oo)17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-
660660 6483-one)(a.k.a.'17-α-methyl-1-testosterone');
661661 649 (pp)Nandrolone(17β-hydroxyestr-4-ene-3-one);
662662 650 (qq)19-nor-4-androstenediol(3β,17β-dihydroxyestr-4-ene);
663663 651 (rr)19-nor-4-androstenediol(3α,17β-dihydroxyestr -4-ene);
664664 652 (ss)19-nor-4,9(10)-androstadienedione(estra-4,9(10)-diene-3,17-dione);
665665 653 (tt)19-nor-5-androstenediol(3β,17β-dihydroxyestr-5-ene);
666666 654 (uu)19-nor-5-androstenediol(3α,17β-dihydroxyestr -5-ene);
667667 655 (vv)19-nor-4-androstenedione(estr-4-en-3,17-dione);
668668 656 (ww)19-nor-5-androstenedione(estr-5-en-3,17-dione);
669669 657 (xx)Norbolethone(13β,17α-diethyl-17β-hydroxygon-4-en-3-one);
670670 658 (yy)Norclostebol(4-chloro-17β-hydroxyestr -4-en-3-one);
671671 659 (zz)Norethandrolone(17α-ethyl-17β-hydroxyestr -4-en-3-one);
672672 660 (aaa)Normethandrolone(17α-methyl-17β-hydroxyestr -4-en-3-one);
673673 661 (bbb)Oxandrolone(17α-methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one);
674674 662 (ccc)Oxymesterone(17α-methyl-4,17β-dihydroxyandrost-4-en-3-one);
675675 663 (ddd)metholone(17α-methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-
676676 664one);
677677 665 (eee)Prostanozol(17β-hydroxy-5α-androstano[3,2-c]pyrazole);
678678 666 (fff)Stanolone(Δ1-dihydrotestosterone(a.k.a.1-testosterone)(17β-hydroxy-5α-
679679 667androst-1-en-3-one));
680680 668 (ggg)Stanozolol(17α-methyl-17ß-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole);
681681 669 (hhh)Stenbolone(17ß-hydroxy-2-methyl-[5α]-androst-1-en-3-one);
682682 670 (iii)Testolactone(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oicacid
683683 671lactone);
684684 672 (jjj)Testosterone(17ß-hydroxyandrost-4-en-3-one);
685685 673 (kkk)Tetrahydrogestrinone(13ß,17α-diethyl-17ß-hydroxygon-4,9,11-trien-3-one);
686686 674 (lll)Trenbolone(17ß-hydroxyestr-4,9,11-trien-3-one);
687687 675 (mmm)Anysalt,ester,oretherofadrugorsubstancedescribedorlistedinthis
688688 676subdivision,exceptananabolicsteroidwhichisexpresslyintendedforadministrationthrough
689689 HB1367 19 677implantstocattleorothernonhumanspeciesandwhichhasbeenapprovedbytheSecretary
690690 678ofHealthandHumanServicesforthatadministration;
691691 679 (7)Dronabinol(synthetic)insesameoilandencapsulatedinasoftgelatincapsuleina
692692 680UnitedStatesFoodandDrugAdministrationapproveddrugproduct;
693693 681 (8)Thedepartmentofhealthandseniorservicesmayexceptbyruleanycompound,
694694 682mixture,orpreparationcontaininganystimulantordepressantsubstancelistedin
695695 683subdivisions(1)and(2)ofthissubsectionfromtheapplicationofalloranypartof
696696 684sections195.010to195.320ifthecompound,mixture,orpreparationcontainsoneormore
697697 685activemedicinalingredientsnothavingastimulantordepressanteffectonthecentralnervous
698698 686system,andiftheadmixturesareincludedthereinincombinations,quantity,proportion,or
699699 687concentrationthatvitiatethepotentialforabuseofthesubstanceswhichhaveastimulantor
700700 688depressanteffectonthecentralnervoussystem.
701701 689 7.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinSchedule
702702 690IVifitfindsthat:
703703 691 (1)ThesubstancehasalowpotentialforabuserelativetosubstancesinScheduleIII;
704704 692 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
705705 693States;and
706706 694 (3)Abuseofthesubstancemayleadtolimitedphysicaldependenceorpsychological
707707 695dependencerelativetothesubstancesinScheduleIII.
708708 696 8.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleIV:
709709 697 (1)Anymaterial,compound,mixture,orpreparationcontaininganyofthefollowing
710710 698narcoticdrugsortheirsaltscalculatedasthefreeanhydrousbaseoralkaloid,inlimited
711711 699quantitiesassetforthbelow:
712712 700 (a)Notmorethanonemilligramofdifenoxinandnotlessthantwenty-five
713713 701microgramsofatropinesulfateperdosageunit;
714714 702 (b)Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-
715715 703propionoxybutane);
716716 704 (c)2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol,itssalts,optical
717717 705andgeometricisomers,andsaltsoftheseisomers(includingtramadol);
718718 706 (d)Anyofthefollowinglimitedquantitiesofnarcoticdrugsortheirsalts,whichshall
719719 707includeoneormorenonnarcoticactivemedicinalingredientsinsufficientproportionto
720720 708conferuponthecompound,mixtureorpreparationvaluablemedicinalqualitiesotherthan
721721 709thosepossessedbythenarcoticdrugalone:
722722 710 a.Notmorethantwohundredmilligramsofcodeineperonehundredmillilitersor
723723 711peronehundredgrams;
724724 712 b.Notmorethanonehundredmilligramsofdihydrocodeineperonehundred
725725 713millilitersorperonehundredgrams;
726726 HB1367 20 714 c.Notmorethanonehundredmilligramsofethylmorphineperonehundred
727727 715millilitersorperonehundredgrams;
728728 716 (2)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
729729 717followingsubstances,includingtheirsalts,isomers,andsaltsofisomerswheneverthe
730730 718existenceofthosesalts,isomers,andsaltsofisomersispossiblewithinthespecificchemical
731731 719designation:
732732 720 (a)Alfaxalone;
733733 721 (b)Alprazolam;
734734 722 (c)Barbital;
735735 723 (d)Bromazepam;
736736 724 (e)Camazepam;
737737 725 (f)Carisoprodol;
738738 726 (g)Chloralbetaine;
739739 727 (h)Chloralhydrate;
740740 728 (i)Chlordiazepoxide;
741741 729 (j)Clobazam;
742742 730 (k)Clonazepam;
743743 731 (l)Clorazepate;
744744 732 (m)Clotiazepam;
745745 733 (n)Cloxazolam;
746746 734 (o)Delorazepam;
747747 735 (p)Diazepam;
748748 736 (q)Dichloralphenazone;
749749 737 (r)Estazolam;
750750 738 (s)Ethchlorvynol;
751751 739 (t)Ethinamate;
752752 740 (u)Ethylloflazepate;
753753 741 (v)Fludiazepam;
754754 742 (w)Flunitrazepam;
755755 743 (x)Flurazepam;
756756 744 (y)Fospropofol;
757757 745 (z)Halazepam;
758758 746 (aa)Haloxazolam;
759759 747 (bb)Ketazolam;
760760 748 (cc)Loprazolam;
761761 749 (dd)Lorazepam;
762762 750 (ee)Lormetazepam;
763763 HB1367 21 751 (ff)Mebutamate;
764764 752 (gg)Medazepam;
765765 753 (hh)Meprobamate;
766766 754 (ii)Methohexital;
767767 755 (jj)Methylphenobarbital(mephobarbital);
768768 756 (kk)Midazolam;
769769 757 (ll)Mifepristone;
770770 758 (mm)Nimetazepam;
771771 759 [(mm)] (nn)Nitrazepam;
772772 760 [(nn)] (oo)Nordiazepam;
773773 761 [(oo)] (pp)Oxazepam;
774774 762 [(pp)] (qq)Oxazolam;
775775 763 [(qq)] (rr)Paraldehyde;
776776 764 [(rr)](ss)Petrichloral;
777777 765 [(ss)](tt)Phenobarbital;
778778 766 [(tt)](uu)Pinazepam;
779779 767 [(uu)] (vv)Prazepam;
780780 768 [(vv)] (ww)Quazepam;
781781 769 [(ww)] (xx)Suvorexant;
782782 770 [(xx)] (yy)Temazepam;
783783 771 [(yy)] (zz)Tetrazepam;
784784 772 [(zz)] (aaa)Triazolam;
785785 773 [(aaa)] (bbb)Zaleplon;
786786 774 [(bbb)] (ccc)Zolpidem;
787787 775 [(ccc)] (ddd)Zopiclone;
788788 776 (3)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
789789 777thefollowingsubstanceincludingitssalts,isomersandsaltsofisomerswheneverthe
790790 778existenceofsuchsalts,isomersandsaltsofisomersispossible:fenfluramine;
791791 779 (4)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
792792 780thefollowingsubstances,includingitssalts,isomers,andsaltsofisomers,wheneverthe
793793 781existenceofsuchsalts,isomers,andsaltsofisomersispossible:Lorcaserin;
794794 782 (5)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
795795 783followingsubstanceshavingastimulanteffectonthecentralnervoussystem,includingtheir
796796 784salts,isomersandsaltsofisomers:
797797 785 (a)Cathine((+)-norpseudoephedrine);
798798 786 (b)Diethylpropion;
799799 787 (c)Fencamfamin;
800800 HB1367 22 788 (d)Fenproporex;
801801 789 (e)Mazindol;
802802 790 (f)Mefenorex;
803803 791 (g)Modafinil;
804804 792 (h)Pemoline,includingorganometalliccomplexesandchelatesthereof;
805805 793 (i)Phentermine;
806806 794 (j)Pipradrol;
807807 795 (k)Sibutramine;
808808 796 (l)SPA((-)-1-dimethyamino-1,2-diphenylethane);
809809 797 (6)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
810810 798followingsubstance,includingitssalts:
811811 799 (a)Butorphanol(includingitsopticalisomers);
812812 800 (b)Eluxadoline(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-
813813 801oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
814814 802acid)(includingitsopticalisomers)anditssalts,isomers,andsaltsofisomers;
815815 803 (c)Pentazocine;
816816 804 (7)Ephedrine,itssalts,opticalisomersandsaltsofopticalisomers,whenthe
817817 805substanceistheonlyactivemedicinalingredient;
818818 806 (8)Thedepartmentofhealthandseniorservicesmayexceptbyruleanycompound,
819819 807mixture,orpreparationcontaininganydepressantsubstancelistedinsubdivision(1)ofthis
820820 808subsectionfromtheapplicationofalloranypartofsections195.010to195.320andsections
821821 809579.015to579.086ifthecompound,mixture,orpreparationcontainsoneormoreactive
822822 810medicinalingredientsnothavingadepressanteffectonthecentralnervoussystem,andifthe
823823 811admixturesareincludedthereinincombinations,quantity,proportion,orconcentrationthat
824824 812vitiatethepotentialforabuseofthesubstanceswhichhaveadepressanteffectonthecentral
825825 813nervoussystem.
826826 814 9.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinScheduleV
827827 815ifitfindsthat:
828828 816 (1)Thesubstancehaslowpotentialforabuserelativetothecontrolledsubstances
829829 817listedinScheduleIV;
830830 818 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
831831 819States;and
832832 820 (3)Thesubstancehaslimitedphysicaldependenceorpsychologicaldependence
833833 821liabilityrelativetothecontrolledsubstanceslistedinScheduleIV.
834834 822 10.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleV:
835835 823 (1)Anycompound,mixtureorpreparationcontaininganyofthefollowingnarcotic
836836 824drugsortheirsaltscalculatedasthefreeanhydrousbaseoralkaloid,inlimitedquantitiesas
837837 HB1367 23 825setforthbelow,whichalsocontainsoneormorenonnarcoticactivemedicinalingredientsin
838838 826sufficientproportiontoconferuponthecompound,mixtureorpreparationvaluablemedicinal
839839 827qualitiesotherthanthosepossessedbythenarcoticdrugalone:
840840 828 (a)Notmorethantwoandfive-tenthsmilligramsofdiphenoxylateandnotlessthan
841841 829twenty-fivemicrogramsofatropinesulfateperdosageunit;
842842 830 (b)Notmorethanonehundredmilligramsofopiumperonehundredmillilitersorper
843843 831onehundredgrams;
844844 832 (c)Notmorethanfive-tenthsmilligramofdifenoxinandnotlessthantwenty-five
845845 833microgramsofatropinesulfateperdosageunit;
846846 834 (2)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityof
847847 835thefollowingsubstancehavingastimulanteffectonthecentralnervoussystemincludingits
848848 836salts,isomersandsaltsofisomers:pyrovalerone;
849849 837 (3)Anycompound,mixture,orpreparationcontaininganydetectablequantityof
850850 838pseudoephedrineoritssaltsoropticalisomers,orsaltsofopticalisomersoranycompound,
851851 839mixture,orpreparationcontaininganydetectablequantityofephedrineoritssaltsoroptical
852852 840isomers,orsaltsofopticalisomers;
853853 841 (4)Unlessspecificallyexemptedorexcludedorunlesslistedinanotherschedule,any
854854 842material,compound,mixture,orpreparationwhichcontainsanyquantityofthefollowing
855855 843substanceshavingadepressanteffectonthecentralnervoussystem,includingitssalts:
856856 844 (a)Brivaracetam((25)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide)(also
857857 845referredtoasBRV;UCB-34714;Briviact);
858858 846 (b)Ezogabine[N-[2-amino-4(4-fluorobenzylamino)-phenyl]-carbamicacidethyl
859859 847ester];
860860 848 (c)Lacosamide[(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];
861861 849 (d)Pregabalin[(S)-3-(aminomethyl)-5-methylhexanoicacid];
862862 850 (5)Anydrugproductinfinisheddosageformulationthathasbeenapprovedbythe
863863 851U.S.FoodandDrugAdministrationthatcontainscannabidiol(2-[1R-3-methyl-6R-(1-
864864 852methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol)derivedfromcannabisandno
865865 853morethan0.1percent(w/w)residualtetrahydrocannabinols.
866866 854 11.Ifanycompound,mixture,orpreparationasspecifiedinsubdivision(3)of
867867 855subsection10ofthissectionisdispensed,sold,ordistributedinapharmacywithouta
868868 856prescription:
869869 857 (1)Allpackagesofanycompound,mixture,orpreparationcontaininganydetectable
870870 858quantityofpseudoephedrine,itssaltsoropticalisomers,orsaltsofopticalisomersor
871871 859ephedrine,itssaltsoropticalisomers,orsaltsofopticalisomers,shallbeofferedforsaleonly
872872 860frombehindapharmacycounterwherethepublicisnotpermitted,andonlybyaregistered
873873 861pharmacistorregisteredpharmacytechnician;and
874874 HB1367 24 862 (2)Anypersonpurchasing,receivingorotherwiseacquiringanycompound,mixture,
875875 863orpreparationcontaininganydetectablequantityofpseudoephedrine,itssaltsoroptical
876876 864isomers,orsaltsofopticalisomersorephedrine,itssaltsoropticalisomers,orsaltsofoptical
877877 865isomersshallbeatleasteighteenyearsofage;and
878878 866 (3)Thepharmacist,internpharmacist,orregisteredpharmacytechnicianshallrequire
879879 867anyperson,priortosuchperson'spurchasing,receivingorotherwiseacquiringsuch
880880 868compound,mixture,orpreparationtofurnishsuitablephotoidentificationthatisissuedbya
881881 869stateorthefederalgovernmentoradocumentthat,withrespecttoidentification,is
882882 870consideredacceptableandshowingthedateofbirthoftheperson;
883883 871 (4)Thesellershalldelivertheproductdirectlyintothecustodyofthepurchaser.
884884 872 12.Pharmacists,internpharmacists,andregisteredpharmacytechniciansshall
885885 873implementandmaintainanelectroniclogofeachtransaction.Suchlogshallincludethe
886886 874followinginformation:
887887 875 (1)Thename,address,andsignatureofthepurchaser;
888888 876 (2)Theamountofthecompound,mixture,orpreparationpurchased;
889889 877 (3)Thedateandtimeofeachpurchase;and
890890 878 (4)Thenameorinitialsofthepharmacist,internpharmacist,orregisteredpharmacy
891891 879technicianwhodispensedthecompound,mixture,orpreparationtothepurchaser.
892892 880 13.Eachpharmacyshallsubmitinformationregardingsalesofanycompound,
893893 881mixture,orpreparationasspecifiedinsubdivision(3)ofsubsection10ofthissectionin
894894 882accordancewithtransmissionmethodsandfrequencyestablishedbythedepartmentby
895895 883regulation;
896896 884 14.Nopersonshalldispense,sell,purchase,receive,orotherwiseacquirequantities
897897 885greaterthanthosespecifiedinthischapter.
898898 886 15.Allpersonswhodispenseorofferforsalepseudoephedrineandephedrine
899899 887productsinapharmacyshallensurethatallsuchproductsarelocatedonlybehindapharmacy
900900 888counterwherethepublicisnotpermitted.
901901 889 16.Thepenaltiesforaknowingorrecklessviolationoftheprovisionsofsubsections
902902 89011to15ofthissectionarefoundinsection579.060.
903903 891 17.Theschedulingofsubstancesspecifiedinsubdivision(3)ofsubsection10ofthis
904904 892sectionandsubsections11,12,14,and15ofthissectionshallnotapplytoanycompounds,
905905 893mixtures,orpreparationsthatareinliquidorliquid-filledgelcapsuleformortoany
906906 894compound,mixture,orpreparationspecifiedinsubdivision(3)ofsubsection10ofthis
907907 895sectionwhichmustbedispensed,sold,ordistributedinapharmacypursuanttoa
908908 896prescription.
909909 897 18.Themanufacturerofadrugproductoranotherinterestedpartymayapplywith
910910 898thedepartmentofhealthandseniorservicesforanexemptionfromthissection.The
911911 HB1367 25 899departmentofhealthandseniorservicesmaygrantanexemptionbyrulefromthissectionif
912912 900thedepartmentfindsthedrugproductisnotusedintheillegalmanufactureof
913913 901methamphetamineorothercontrolledordangeroussubstances.Thedepartmentofhealth
914914 902andseniorservicesshallrelyonreportsfromlawenforcementandlawenforcement
915915 903evidentiarylaboratoriesindeterminingiftheproposedproductcanbeusedtomanufacture
916916 904illicitcontrolledsubstances.
917917 905 19.Thedepartmentofhealthandseniorservicesshallreviseandrepublishthe
918918 906schedulesannually.
919919 907 20.Thedepartmentofhealthandseniorservicesshallpromulgaterulesunderchapter
920920 908536regardingthesecurityandstorageofScheduleVcontrolledsubstances,asdescribedin
921921 909subdivision(3)ofsubsection10ofthissection,fordistributorsasregisteredbythe
922922 910departmentofhealthandseniorservices.
923923 911 21.Logsoftransactionsrequiredtobekeptandmaintainedbythissectionand
924924 912section195.417shallcreatearebuttablepresumptionthatthepersonwhosenameappearsin
925925 913thelogsisthepersonwhosetransactionsarerecordedinthelogs.
926926 579.018.1.Apersoncommitstheoffenseofcoercedcriminalabortionbymeans
927927 2offraudifthepersonknowinglyandintentionallyengagesintheuseofanabortion-
928928 3inducingdrugonapregnantwomanwithoutherknowledgeorconsentwiththeintent
929929 4tocauseanabortion.
930930 5 2.TheoffenseofcoercedcriminalabortionbymeansoffraudisaclassBfelony.
931931 6 3.Aprosecutionofapersonunderthissectionshallnotbeadefenseagainsta
932932 7prosecutionunderanyotherprovisionoflaw,includingmurder,ifthepersoncommits
933933 8theoffenseofcoercedcriminalabortionbymeansoffraudandtheuseofanabortion-
934934 9inducingdrugresultsinthedeathorseriousbodilyinjuryofthepregnantwoman.
935935 ✔
936936 HB1367 26